Literature DB >> 7907656

Transforming growth factor alpha and CD68 immunoreactivity in giant cell tumours of bone: a study on the nature of stromal and giant cells, and their interrelations.

T Hasegawa1, T Hirose, K Seki, T Sano, K Hizawa.   

Abstract

To clarify the nature of neoplastic cells, 17 giant cell tumours of bone were studied histologically and immunohistochemically. L1 antigen and S-100 protein were not detected in the tumour giant cells and stromal cells, although present in non-neoplastic macrophages. The giant cells in all the lesions, some stromal cells, and osteoclasts in the normal bone showed CD68 and transforming growth factor alpha (TGF alpha) immunoreactivity. Fibrohistiocytic antigen, factor XIIIa, was expressed in large numbers of stromal cells in all lesions. Some stromal cells expressed alpha-smooth muscle actin and osteocalcin. These immunohistochemical results suggested that the stromal cells of giant cell tumours of bone showed histiocytic and occasional myofibroblastic and osteoblastic differentiation. Proliferating cell nuclear antigen was demonstrated in the nuclei of the stromal cells only, indicating that these were the sole proliferating elements. TGF alpha produced by the giant cells and some stromal cells may play a role as a mediator for the attraction and/or proliferation of the precursor cells, and may suppress the activity of osteoblastic stromal cells, resulting in restricted bone formation in giant cell tumours.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7907656     DOI: 10.1002/path.1711700314

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  3 in total

1.  miR-181c associates with tumor relapse of high grade osteosarcoma.

Authors:  Federica Mori; Andrea Sacconi; Valeria Canu; Federica Ganci; Mariangela Novello; Vincenzo Anelli; Renato Covello; Virginia Ferraresi; Paola Muti; Roberto Biagini; Giovanni Blandino; Sabrina Strano
Journal:  Oncotarget       Date:  2015-06-10

2.  Histopathological, immunohistochemical, and image analytic parameters characterizing the stromal component in primary and recurrent giant cell tumor of bone.

Authors:  Charu Chandra Saxena; Rajni Safaya; Neha Kawatra Madan; Shah Alam Khan; Venkateswaran K Iyer
Journal:  J Clin Orthop Trauma       Date:  2015-10-26

3.  Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy.

Authors:  Matthew R Steensma; Wakenda K Tyler; Allison G Shaber; Steven R Goldring; F Patrick Ross; Bart O Williams; John H Healey; P Edward Purdue
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.